| Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors P Valent, E Hadzijusufovic, GH Schernthaner, D Wolf, D Rea, P le Coutre Blood, The Journal of the American Society of Hematology 125 (6), 901-906, 2015 | 299 | 2015 |
| Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts P Valent, C Akin, K Hartmann, G Nilsson, A Reiter, O Hermine, K Sotlar, ... Theranostics 10 (23), 10743, 2020 | 132 | 2020 |
| Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site E Hadzijusufovic, K Albrecht-Schgoer, K Huber, G Hoermann, F Grebien, ... Leukemia 31 (11), 2388-2397, 2017 | 129 | 2017 |
| Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis G Greiner, B Sprinzl, A Górska, F Ratzinger, M Gurbisz, N Witzeneder, ... Blood, The Journal of the American Society of Hematology 137 (2), 238-247, 2021 | 124 | 2021 |
| International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study WR Sperr, M Kundi, I Alvarez-Twose, B van Anrooij, JNGO Elberink, ... The Lancet Haematology 6 (12), e638-e649, 2019 | 124 | 2019 |
| The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease G Hoermann, KV Gleixner, GE Dinu, M Kundi, G Greiner, F Wimazal, ... Allergy 69 (6), 810-813, 2014 | 112 | 2014 |
| Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536 KV Gleixner, V Ferenc, B Peter, A Gruze, RA Meyer, E Hadzijusufovic, ... Cancer research 70 (4), 1513-1523, 2010 | 110 | 2010 |
| A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection R Saleh, G Wedeh, H Herrmann, S Bibi, S Cerny-Reiterer, I Sadovnik, ... Blood, The Journal of the American Society of Hematology 124 (1), 111-120, 2014 | 96 | 2014 |
| KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib KV Gleixner, M Mayerhofer, S Cerny-Reiterer, G Hörmann, U Rix, ... Blood, The Journal of the American Society of Hematology 118 (7), 1885-1898, 2011 | 79 | 2011 |
| Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML P Valent, E Hadzijusufovic, G Hoermann, W Füreder, GH Schernthaner, ... Leukemia research 59, 47-54, 2017 | 73 | 2017 |
| Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML H Emir, K Albrecht-Schgoer, K Huber, F Grebien, G Eisenwort, W Schgoer, ... Blood 122 (21), 257, 2013 | 68 | 2013 |
| Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells KV Gleixner, L Rebuzzi, M Mayerhofer, A Gruze, E Hadzijusufovic, ... Experimental Hematology 35 (10), 1510-1521, 2007 | 68 | 2007 |
| The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis M Schneeweiss, B Peter, S Bibi, G Eisenwort, D Smiljkovic, K Blatt, ... Haematologica 103 (5), 799, 2018 | 66 | 2018 |
| Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy S Bibi, MD Arslanhan, F Langenfeld, S Jeanningros, S Cerny-Reiterer, ... Haematologica 99 (3), 417, 2014 | 63 | 2014 |
| European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. P Valent, M Arock, P Bonadonna, K Brockow, S Broesby-Olsen, ... Wiener klinische Wochenschrift 124, 2012 | 58* | 2012 |
| Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth B Peter, GE Winter, K Blatt, KL Bennett, G Stefanzl, U Rix, G Eisenwort, ... Leukemia 30 (2), 464-472, 2016 | 57 | 2016 |
| H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells E Hadzijusufovic, B Peter, KV Gleixner, K Schuch, WF Pickl, T Thaiwong, ... Experimental hematology 38 (10), 896-907, 2010 | 56 | 2010 |
| The data registry of the European Competence Network on Mastocytosis (ECNM): set up, projects, and perspectives P Valent, JNGO Elberink, A Gorska, M Lange, R Zanotti, B van Anrooij, ... The Journal of Allergy and Clinical Immunology: In Practice 7 (1), 81-87, 2019 | 52 | 2019 |
| Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V KV Gleixner, B Peter, K Blatt, V Suppan, A Reiter, D Radia, ... Haematologica 98 (9), 1450, 2013 | 52 | 2013 |
| Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis K Blatt, S Cerny-Reiterer, J Schwaab, K Sotlar, G Eisenwort, G Stefanzl, ... Blood, The Journal of the American Society of Hematology 126 (26), 2832-2841, 2015 | 51 | 2015 |
Giulio Superti-FurgaScientific Director, CeMM Research Center for Molecular Medicine of the Austrian Academy ofVerified email at cemm.oeaw.ac.at
